These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26137111)

  • 1. NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells.
    Wang X; Jia L; Jin X; Liu Q; Cao W; Gao X; Yang M; Sun B
    Oncol Lett; 2015 Jun; 9(6):2586-2590. PubMed ID: 26137111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
    Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
    Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscone restores anoikis sensitivity in TMZ-resistant glioblastoma cells by suppressing TOP2A via the EGFR/Integrin β1/FAK signaling pathway.
    Zou Y; Xu L; Wang W; Zhu X; Lin J; Li H; Chen J; Xu W; Gao H; Wu X; Yin Z; Wang Q
    Phytomedicine; 2024 Jul; 129():155714. PubMed ID: 38723526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.
    Li M; Liang RF; Wang X; Mao Q; Liu YH
    Oncol Lett; 2017 Dec; 14(6):6597-6603. PubMed ID: 29151909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway.
    Tang Q; Cao H; Tong N; Liu Y; Wang W; Zou Y; Xu L; Zeng Z; Xu W; Yin Z; Ma W; Wang Q
    Phytomedicine; 2022 May; 99():154016. PubMed ID: 35278900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
    Qiu ZK; Shen D; Chen YS; Yang QY; Guo CC; Feng BH; Chen ZP
    Chin J Cancer; 2014 Feb; 33(2):115-22. PubMed ID: 23958055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
    Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
    Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide resistance in glioblastoma multiforme.
    Lee SY
    Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
    Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
    Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forkhead box protein O3a promotes glioma cell resistance to temozolomide by regulating matrix metallopeptidase and β-catenin.
    Sun D; Yang S; Zhang X; Li S; Wang L; Chen J; Qiu C; Xu K
    Oncol Lett; 2021 Apr; 21(4):328. PubMed ID: 33692860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
    Kundu M; Das S; Nandi S; Dhara D; Mandal M
    Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166782. PubMed ID: 37286145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic analysis identifies the neuropeptide cortistatin (CORT) as an inhibitor of temozolomide (TMZ) resistance by suppressing the NF-κB-MGMT signaling axis in human glioma.
    He Z; Peng B; Wang Q; Tian J; Liu P; Feng J; Liao Y; Chen L; Jia P; Tang J
    Genes Dis; 2024 May; 11(3):100977. PubMed ID: 38292193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
    Haemmig S; Baumgartner U; Glück A; Zbinden S; Tschan MP; Kappeler A; Mariani L; Vajtai I; Vassella E
    Cell Death Dis; 2014 Jun; 5(6):e1279. PubMed ID: 24901050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional control of O
    Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
    J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiated embryonic chondrocyte-expressed gene 1 promotes temozolomide resistance by modulating the SP1-MGMT axis in glioblastoma.
    Lv W; Li Q; Jia B; He Y; Ru Y; Guo Q; Li X; Lin W
    Am J Transl Res; 2021; 13(4):2331-2349. PubMed ID: 34017393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
    Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
    Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells.
    Song T; Li H; Tian Z; Xu C; Liu J; Guo Y
    Onco Targets Ther; 2015; 8():2199-208. PubMed ID: 26346978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.